- Home
- AGEN vs IGI Comparison
AGEN vs IGI Comparison
Compare AGEN & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- IGI
- Stock Information
- Founded
- AGEN 1994
- IGI 2009
- Country
- AGEN United States
- IGI United States
- Employees
- AGEN N/A
- IGI N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- IGI Investment Managers
- Sector
- AGEN Health Care
- IGI Finance
- Exchange
- AGEN Nasdaq
- IGI Nasdaq
- Market Cap
- AGEN 87.7M
- IGI 99.0M
- IPO Year
- AGEN 2000
- IGI N/A
- Fundamental
- Price
- AGEN $5.29
- IGI $16.54
- Analyst Decision
- AGEN Strong Buy
- IGI
- Analyst Count
- AGEN 3
- IGI 0
- Target Price
- AGEN $16.33
- IGI N/A
- AVG Volume (30 Days)
- AGEN 1.2M
- IGI 33.9K
- Earning Date
- AGEN 08-11-2025
- IGI 01-01-0001
- Dividend Yield
- AGEN N/A
- IGI 4.79%
- EPS Growth
- AGEN N/A
- IGI N/A
- EPS
- AGEN N/A
- IGI N/A
- Revenue
- AGEN $99,524,000.00
- IGI N/A
- Revenue This Year
- AGEN $25.31
- IGI N/A
- Revenue Next Year
- AGEN N/A
- IGI N/A
- P/E Ratio
- AGEN N/A
- IGI N/A
- Revenue Growth
- AGEN N/A
- IGI N/A
- 52 Week Low
- AGEN $1.38
- IGI $15.13
- 52 Week High
- AGEN $7.34
- IGI $17.79
- Technical
- Relative Strength Index (RSI)
- AGEN 44.92
- IGI 55.82
- Support Level
- AGEN $5.34
- IGI $16.49
- Resistance Level
- AGEN $6.58
- IGI $16.60
- Average True Range (ATR)
- AGEN 0.44
- IGI 0.13
- MACD
- AGEN -0.16
- IGI 0.01
- Stochastic Oscillator
- AGEN 10.69
- IGI 83.33
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.